A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN (TC) VERSUS PACLITAXEL PLUS CISPLATIN (TP) IN STAGE IVB OR RECURRENT CERVICAL CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0505)

被引：0
|
作者：
Kitagawa, R. [1 ]
Katsumata, N.
Shibata, T.
Nakanishi, T. [2 ]
Nishimura, S. [3 ]
Nishio, S. [4 ]
Takano, M. [5 ]
Satoh, T. [6 ]
Yokota, H. [7 ]
Ochiai, K. [8 ]
Kigawa, J. [9 ]
Kobayashi, H. [10 ]
Kanato, K. [11 ]
Yoshikawa, H. [6 ]
Kamura, T. [4 ]
机构：
[1] NTT Med Ctr Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Gynecol Oncol, Aichi, Japan
[3] Osaka City Gen Hosp, Dept Gynecol Oncol, Osaka, Japan
[4] Kurume Univ, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan
[5] Natl Def Med Coll Hosp, Dept Obstet & Gynecol, Tokorozawa, Saitama, Japan
[6] Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 305, Japan
[7] Saitama Canc Ctr, Dept Gynecol Oncol, Saitama, Japan
[8] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[9] Tottori Univ, Dept Obstet & Gynecol, Yonago, Tottori, Japan
[10] Kyushu Univ, Dept Obstet & Gynecol, Fukuoka 812, Japan
[11] Natl Canc Ctr, Multiinst Clin Trial Support Ctr, JCOG Operat Off, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [1] A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505)
    Kitagawa, Ryo
    Katsumata, Noriyuki
    Shibata, Taro
    Nakanishi, Toru
    Nishimura, Sadako
    Ushijima, Kimio
    Takano, Masashi
    Satoh, Toyomi
    Yoshikawa, Hiroyuki
    Kamura, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)
    Saito, Isamu
    Kitagawa, Ryo
    Fukuda, Haruhiko
    Shibata, Taro
    Katsumata, Noriyuki
    Konishi, Ikuo
    Yoshikawa, Hiroyuki
    Kamura, Toshiharu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 90 - 93
  • [3] Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
    Kitagawa, Ryo
    Katsumata, Noriyuki
    Shibata, Taro
    Kamura, Toshiharu
    Kasamatsu, Takahiro
    Nakanishi, Toru
    Nishimura, Sadako
    Ushijima, Kimio
    Takano, Masashi
    Satoh, Toyomi
    Yoshikawa, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2129 - U151
  • [4] DOES PACLITAXEL PLUS CARBOPLATIN (TC) SUBSTITUTE FOR PACLITAXEL PLUS CISPLATIN (TP) IN CERVICAL CANCER WITHOUT PRIOR PLATINUM TREATMENT? (SUBSET ANALYSIS OF JAPAN CLINICAL ONCOLOGY GROUP TRIAL (JCOG 0505))
    Tanabe, H.
    Kitagawa, R.
    Shibata, T.
    Saito, M.
    Takakura, S.
    Okamoto, A.
    Sasaki, H.
    Ochiai, K.
    Yoshikawa, H.
    Kamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 327 - 327
  • [5] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
    Shin Nishio
    Ryo Kitagawa
    Taro Shibata
    Hiroyuki Yoshikawa
    Ikuo Konishi
    Kimio Ushijima
    Toshiharu Kamura
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 785 - 790
  • [6] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
    Nishio, Shin
    Kitagawa, Ryo
    Shibata, Taro
    Yoshikawa, Hiroyuki
    Konishi, Ikuo
    Ushijima, Kimio
    Kamura, Toshiharu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 785 - 790
  • [7] A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
    Kitagawa, Ryo
    Ishikawa, Mitsuya
    Shibata, Taro
    Miyamoto, Kenichi
    Kobayashi, Hiroaki
    Onda, Takashi
    Takekuma, Munetaka
    Takahashi, Fumiaki
    Yokota, Harushige
    Tanikawa, Michihiro
    Mizuno, Mika
    Oishi, Tetsuro
    Aoki, Yoichi
    Nishio, Shin
    Iwata, Takashi
    Yaegashi, Nobuo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311)
    Ishikawa, Mitsuya
    Nakamura, Kenichi
    Shibata, Taro
    Tanaka, Kiyo
    Kitagawa, Ryo
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1096 - 1100
  • [9] A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study
    Bae-Jump, Victoria L.
    Sill, Michael W.
    Gehrig, Paola A.
    Merker, Jason D.
    Corcoran, David L.
    Pfefferle, Adam D.
    Hayward, Michele C.
    Walker, Joan L.
    Hagemann, Andrea R.
    Waggoner, Steven E.
    O'Cearbhaill, Roisin E.
    Mcdonald, Megan E.
    Edelson, Mitchell I.
    Disilvestro, Paul A.
    Mcnally, Amy L.
    Fleury, Aimee
    Littell, Ramey D.
    Ueland, Frederick R.
    Lankes, Heather A.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2025, 195 : 66 - 74
  • [10] A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study
    Bae-Jump, V. L.
    Sill, M.
    Gehrig, P. A.
    Moxley, K.
    Hagemann, A. R.
    Waggoner, S. E.
    O'Cearbhaill, R. E.
    McDonald, M.
    DiSilvestro, P. A.
    Sperduto, P.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 7 - 7
12345